Venclexta Out Of The Starting Gate With Approval In High-Risk CLL Subset
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche/Abbvie’s first-in-class breakthrough BCL-2 inhibitor granted accelerated approval by FDA in relapsed CLL with 17p deletion.